Klaria Pharma Holding AB (FRA:6FN) Moat Score: 0/10 (As of Jul. 01, 2026)


FRA:6FN Klaria Pharma Holding AB FRA:6FN
28 GF Score
Price €0.06
GF Value €0.03
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Klaria Pharma Holding AB Moat Score?

Klaria Pharma Holding AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Klaria Pharma Holding AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Klaria Pharma Holding AB might have No Moat - No discernible moat.

Klaria Pharma Holding AB  (FRA:6FN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Klaria Pharma Holding AB Moat Score Related Terms

FRA:6FN
28GF Score
Klaria Pharma Holding AB FRA:6FN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of €0.06 is trading 106.3% above its estimated GF Value™ of €0.03. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:6FN:

  • Moat Score: 0
  • GF Value™: €0.03 vs. price of €0.06 (106.3% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Klaria Pharma Holding AB Business Description

Other Exchanges KLAR:Sweden
Address Virdings Alle 2, Uppsala, CHE, 754 50
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
28GF Score

Get the complete analysis for FRA:6FN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price
€0.03
GF Value